{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:01:05Z","timestamp":1788433265889,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":813,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jtct.2020.12.009","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T10:46:02Z","timestamp":1611830762000},"page":"244.e1-244.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study"],"prefix":"10.1016","volume":"27","author":[{"given":"Beatrice Anna","family":"Zannetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Saraceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Guarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Laszlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Imola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Chiarucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Zuffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_4","key":"10.1016\/j.jtct.2020.12.009_bib0001","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2020.12.009_bib0002","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","article-title":"Management of multiple myeloma in the newly diagnosed patient","volume":"2017","author":"Mateos","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2020.12.009_bib0003","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2020.12.009_bib0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2020.12.009_bib0005","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2020.12.009_bib0006","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/s41409-018-0153-1","article-title":"Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report","volume":"53","author":"Passweg","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0007","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2020.12.009_bib0008","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2020.12.009_bib0009","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.bbmt.2019.07.004","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1182\/hematology.2019000015","article-title":"Roundtable: How I treat a newly diagnosed patient with high-risk myeloma","volume":"2019","author":"Kaufman","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2020.12.009_bib0011","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.transci.2017.11.028","article-title":"Current status of art mobilization in myeloma","volume":"56","author":"Sevindik","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtct.2020.12.009_bib0012","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.clml.2018.12.010","article-title":"Hematopoietic progenitor cell mobilization for autologous stem cell transplantation in multiple myeloma in contemporary era","volume":"19","author":"Arora","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2020.12.009_bib0013","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.12.009_bib0014","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2020.12.009_bib0015","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","article-title":"Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"20","author":"Duong","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0016","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty M","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0017","first-page":"1","article-title":"Structural and functional features of the CD34 antigen: an update","volume":"15","author":"Lanza","year":"2001","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.jtct.2020.12.009_bib0018","first-page":"247","article-title":"Single platform enumeration of viable CD34(pos) cells","volume":"17","author":"Keeney","year":"2003","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.jtct.2020.12.009_bib0019","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41409-017-0051-y","article-title":"Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score","volume":"53","author":"Olivieri","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0020","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.bbmt.2013.08.005","article-title":"Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European Group for Blood and Marrow Transplantation","volume":"19","author":"Lanza","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0021","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose Cy and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0022","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jca.21360","article-title":"Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"30","author":"Tuchman","year":"2015","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jtct.2020.12.009_bib0023","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/sj.leu.2405035","article-title":"Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients","volume":"22","author":"Mazumder","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2020.12.009_bib0024","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bmt.2015.236","article-title":"A randomized phase II study of stem cell mobilization with cyclophosphamide\u00a0+\u00a0G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma","volume":"51","author":"Silvennoinen","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0025","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3816\/CLM.2006.n.014","article-title":"Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma","volume":"6","author":"Dingli","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.jtct.2020.12.009_bib0026","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bmt.2015.190","article-title":"Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation","volume":"50","author":"Uy","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0027","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbmt.2017.10.008","article-title":"Chemotherapy-based stem cell mobilization does not result in significant paraprotein reduction in myeloma patients in the era of novel induction regimens","volume":"24","author":"Oyekunle","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0028","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00432-016-2270-9","article-title":"Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients","volume":"142","author":"Winkelmann","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtct.2020.12.009_bib0029","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2012.01.005","article-title":"Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies","volume":"18","author":"Hamadani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0030","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bmt.1702879","article-title":"A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients","volume":"27","author":"Fitoussi","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0031","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.bmt.1703840","article-title":"Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma","volume":"31","author":"Jantunen","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0032","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jca.21283","article-title":"Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma","volume":"28","author":"Shimura","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jtct.2020.12.009_bib0033","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/bmt.2014.330","article-title":"Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective","volume":"50","author":"Saraceni","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0034","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.12.009_bib0035","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/bmt.2015.23","article-title":"G-CSF plus preemptive plerixafor vs hyperfractionated Cy plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis","volume":"50","author":"Antar","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0036","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bmt.2015.322","article-title":"Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study","volume":"51","author":"Afifi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0037","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/bmt.2013.52","article-title":"Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies","volume":"48","author":"Awan","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0038","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbmt.2010.08.018","article-title":"Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide","volume":"17","author":"Shaughnessy","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0039","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bmt.2010.170","article-title":"Growth factor and patient-adapted use of plerixafor is superior to Cy and growth factor for autologous hematopoietic stem cells mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2012.08.010","article-title":"Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization","volume":"19","author":"Micallef","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0041","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/trf.12265","article-title":"Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma","volume":"54","author":"Lanza","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2020.12.009_bib0042","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/ajh.24817","article-title":"A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach","volume":"92","author":"Lanza","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2020.12.009_bib0043","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1517\/14712598.2015.971750","article-title":"Plerixafor: what we still have to learn","volume":"15","author":"Lanza","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jtct.2020.12.009_bib0044","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bmt.2014.196","article-title":"Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization","volume":"50","author":"S\u00e1nchez-Ortega","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.12.009_bib0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/10428194.2017.1324161","article-title":"Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma","volume":"59","author":"Milone","year":"2018","journal-title":"Leuk Lymphoma"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636720300531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636720300531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:59:33Z","timestamp":1763002773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636720300531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2666636720300531"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2020.12.009","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2020.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}